Aberrant genomic or expressional changes of BCL6 have been detected in lymphomas and multiple solid tumors, including breast cancer, glioblastoma or ovarian cancer (Walker et al., 2015; Wang et al., 2015; Xu et al., 2017). Here, BCL6 is linked to breast carcinoma.